Status:
UNKNOWN
Radiofrequency Ablation Combined With Recombinant Human Adenovirus Type 5 in the Treatment of Hepatocellular Carcinoma.
Lead Sponsor:
Southwest Hospital, China
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The primary reason for recurrence of hepatocellular carcinoma after radiofrequency ablation (RFA) is the micro-metastatic lesion that has not been ablated and inactivated in the transitional area.Some...
Detailed Description
The primary reason for recurrence of hepatocellular carcinoma after radiofrequency ablation (RFA) is the micro-metastatic lesion that has not been ablated and inactivated in the transitional area.Onco...
Eligibility Criteria
Inclusion
- The patients understand the content and significance of the study and we obtain a written informed consent from them.
- The patients' gender are not limited and are between the ages of 18 and 75.
- Liver function of Child-Pugh Class A or B;The retention rate of indocyanine green for 15 minutes is less than or equal to 20%.
- The ECOG score is 0.
- The diagnosis was a single hepatocellular carcinoma with a diameter of no more than 3cm.
- There were no other related diseases affecting RFA treatment.
Exclusion
- There are tumor emboli in the large vessels of the liver;distant metastasis of HCC.
- The patient has or has had a history of refractory ascites,hepatic encephalopathy, or esophageal varices hemorrhage.
- The patient was complicated with other malignant tumors.
- The patient has severe cardiac, renal and other organ dysfunction.
- In addition to viral hepatitis, there are other active infectious diseases.
Key Trial Info
Start Date :
October 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2020
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT03790059
Start Date
October 1 2016
End Date
September 1 2020
Last Update
October 16 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of hepatobiliary surgery,Southwest Hospital
Chongqing, Chongqing Municipality, China, 400038
2
Institute of hepatobiliary surgery,Southwest Hospital
Chongqing, China, 400038